$KVUE

Kenvue (KVUE) is highlighted as a strong high-yield dividend stock with a 4.68% yield and 64 years of consecutive dividend increases. Its stable of well-known brands reported Q2 revenue of $3.95B and EPS of $0.24. The company is being acquired by Kimberly-Clark (KMB), another Dividend King, which may create uncertainty about Kenvue's dividend.

Colgate-Palmolive (CL) is exploring the sale of Softsoap, Irish Spring, and Speed Stick, with Goldman Sachs advising. North America revenue fell 3% in Q2 2026, and the company aims to fund premium innovation. Shares were at $87.49 in premarket trading on September 14, 2026, down 3.7% over one week but up 9.9% year to date. Potential buyers include private equity firms, with strategic acquirers facing scale or leverage limitations.

Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The EU is expected to formally raise its concerns this week, with Kimberly-Clark facing a September 29 deadline to submit concessions or face a full investigation. The deal has already received conditional approval in Australia and South Africa.

Kimberly-Clark (KMB) extended its 54-year dividend increase streak to $5.12 annualized while closing a $48.7 billion Kenvue (KVUE) acquisition, raising concerns about its balance sheet. Operating cash flow of $2.8 billion covers dividends and capex, but leaves little cushion. KMB shares fell 20% to $98, pushing the yield to 5%. The company's dividend streak and acquisition are under scrutiny as investors assess the financial impact.

A study in Denmark found that prenatal Tylenol (acetaminophen) exposure may reduce ovarian reserves and uterine size in daughters, but long-term effects on fertility are unknown. Researchers studied 302 infants and 1,210 girls, finding smaller ovaries and uteruses in those exposed. The FDA and ACOG state no clear evidence of harm, while Kenvue, which owns Tylenol, defends its safety. Texas sued Kenvue over advertising claims, with one case ongoing.

Kenvue (KVUE) shares fell 3.6% as Kimberly-Clark's 4.5% drop reduced the implied value of Kenvue's acquisition deal to $17.87. The decline follows Kimberly-Clark's outlook of slower growth and supply-chain issues. The merger, pending regulatory approvals, is partly driving Kenvue's stock movement.

Australia's ACCC approved Kimberly-Clark's $40B Kenvue acquisition, requiring divestment of Kenvue's Carefree and Stayfree brands to maintain competition. The deal awaits EU approval.

Kimberly-Clark (KMB) seeks EU approval for its $40B acquisition of Kenvue, aiming to create a company with $32B in annual revenue and $2.1B in cost savings. The deal would expand KMB's portfolio with brands like Tylenol and Neutrogena, but regulatory and execution risks remain.

Kenvue Inc. reported an 18.9% increase in adjusted earnings to 63 cents per share in the first half of 2026, with adjusted operating margin rising 180 basis points to 23.1%. Revenue growth was modest at 1.2%, and the company faces risks from tariffs, inflation, and debt. Cost discipline and restructuring efforts supported profitability, with expected annual savings of $200 million. The second quarter saw a decline in gross margin due to inflation and foreign exchange impacts. Skin Health and Bea

Kenvue Inc. (KVUE) is nearing a deal with Kimberly-Clark Corp. (KMB), expected to close in Q4 2026 pending foreign regulatory approvals. Kenvue shareholders will receive 0.14625 KMB shares plus $3.50 in cash per share, owning 46% of the combined company. Kenvue has not provided financial guidance due to the pending deal, which may impact business operations and transaction benefits.